Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacibertinib + AI vs Lapatinib + Capecitabine in HER2+/ER+ Advanced Breast Cancer
NCT06313983Phase 3Recruiting
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sacibertinib in breast cancer, sponsored by Tianjin Hemay Biotech. Started Jan 2022; status: recruiting.
02
Drugs
sacibertinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06313983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313983.